

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-60. (Canceled)

¹ ~~61~~. (Previously Presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:299, wherein said polypeptide is expressed in breast tumor tissue.

² ~~62~~. (Previously Presented) An isolated polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO:299, wherein said polypeptide is expressed in breast tumor tissue.

³ ~~63~~. (Previously Presented) An isolated polypeptide according to claim ~~62~~, wherein said polypeptide is at least 95% identical to the amino acid sequence of SEQ ID NO:299.

⁴ ~~64~~. (Previously Presented) An isolated polypeptide comprising the amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:292.

⁵ ~~65~~. (Previously Presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:299.

¹ ⁵ ⁶ ~~66~~. (Previously Presented) An isolated polypeptide according to any one of claims ~~61-65~~, in combination with a physiologically acceptable carrier.

¹ ⁵ ⁷ ~~67~~. (Previously Presented) An isolated polypeptide according to any one of claims ~~61-65~~, in combination with an immunostimulant.

⁶ ~~68~~. (Previously Presented) An isolated polypeptide according to claim ~~67~~, wherein said immunostimulant is an adjuvant.

⁹ ~~69~~. (Previously Presented) An isolated polypeptide according to claim ~~67~~, wherein said immunostimulant induces a predominantly Type I response.